B+L acquires option for Mimetogen's dry eye syndrome drug
This article was originally published in Scrip
Executive Summary
Bausch + Lomb has acquired an option to license Mimetogen Pharmaceuticals' MIM-D3, a potentially first-in-class Phase II compound in development for dry eye syndrome.